Axa’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-9,400
| Closed | -$471K | – | 1202 |
|
|
2021
Q3 | $471K | Hold |
9,400
| – | – | ﹤0.01% | 1069 |
|
|
2021
Q2 | $592K | Hold |
9,400
| – | – | ﹤0.01% | 1074 |
|
|
2021
Q1 | $873K | Hold |
9,400
| – | – | ﹤0.01% | 994 |
|
|
2020
Q4 | $842K | Hold |
9,400
| – | – | ﹤0.01% | 994 |
|
|
2020
Q3 | $971K | Buy |
+9,400
| New | +$1.01M | ﹤0.01% | 939 |
|
|
2020
Q2 | – | Sell |
-5,100
| Closed | -$295K | – | 1247 |
|
|
2020
Q1 | $295K | Buy |
+5,100
| New | +$294K | ﹤0.01% | 1048 |
|
|
2018
Q4 | – | Sell |
-6,400
| Closed | -$421K | – | 1317 |
|
|
2018
Q3 | $421K | Sell |
6,400
-7,200
| -53% | -$420K | ﹤0.01% | 1173 |
|
|
2018
Q2 | $687K | Hold |
13,600
| – | – | ﹤0.01% | 1086 |
|
|
2018
Q1 | $716K | Sell |
13,600
-12,600
| -48% | -$628K | ﹤0.01% | 1078 |
|
|
2017
Q4 | $1.22M | Sell |
26,200
-90,900
| -78% | -$3.83M | ﹤0.01% | 954 |
|
|
2017
Q3 | $4.74M | Buy |
117,100
+109,900
| +1,526% | +$3.98M | 0.02% | 641 |
|
|
2017
Q2 | $244K | Hold |
7,200
| – | – | ﹤0.01% | 1177 |
|
|
2017
Q1 | $209K | Sell |
7,200
-6,535
| -48% | -$199K | ﹤0.01% | 1217 |
|
|
2016
Q4 | $451K | Sell |
13,735
-72,065
| -84% | -$2.16M | ﹤0.01% | 1070 |
|
|
2016
Q3 | $2.71M | Buy |
85,800
+27,800
| +48% | +$808K | 0.01% | 690 |
|
|
2016
Q2 | $1.63M | Sell |
58,000
-28,100
| -33% | -$1.1M | 0.01% | 775 |
|
|
2016
Q1 | $3.13M | Sell |
86,100
-11,800
| -12% | -$417K | 0.01% | 667 |
|
|
2015
Q4 | $3.92M | Sell |
97,900
-300
| -0.3% | -$10.5K | 0.02% | 621 |
|
|
2015
Q3 | $2.8M | Buy |
98,200
+7,200
| +8% | +$237K | 0.01% | 706 |
|
|
2015
Q2 | $3M | Sell |
91,000
-92,000
| -50% | -$2.85M | 0.01% | 705 |
|
|
2015
Q1 | $5.26M | Buy |
183,000
+15,744
| +9% | +$452K | 0.02% | 590 |
|
|
2014
Q4 | $4.55M | Buy |
167,256
+117,256
| +235% | +$2.79M | 0.02% | 580 |
|
|
2014
Q3 | $1.07M | Buy |
50,000
+5,500
| +12% | +$126K | ﹤0.01% | 892 |
|
|
2014
Q2 | $999K | Buy |
44,500
+1,100
| +3% | +$25.6K | ﹤0.01% | 925 |
|
|
2014
Q1 | $1.1M | Sell |
43,400
-5,200
| -11% | -$131K | ﹤0.01% | 903 |
|
|
2013
Q4 | $1.12M | Sell |
48,600
-2,873
| -6% | -$59.9K | 0.01% | 902 |
|
|
2013
Q3 | $981K | Buy |
51,473
+3,173
| +7% | +$56.6K | ﹤0.01% | 874 |
|
|
2013
Q2 | $696K | Buy |
+48,300
| New | +$699K | ﹤0.01% | 901 |
|
Other funds holding EBS
Axa's EBS Position: Q4 2021 in Review
Axa sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 9,400 shares — an estimated $471K sold.
Axa first reported a position in EBS in Q2 2013 and held it in 28 quarters. The position peaked at $5.26M in Q1 2015. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.
- Axa reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
- Axa sold 9,400 Emergent Biosolutions shares in Q4 2021, an estimated $471K.
- Axa first reported a position in Emergent Biosolutions in Q2 2013 and held it in 28 quarters.
- Axa's Emergent Biosolutions position peaked at $5.26M in Q1 2015.
- 254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.
Based on Axa's 13F filing for Q4 2021, filed 14 Feb 2022.